Predictive Clinicopathologic Features and Prognostic Assessment of Pt0 Prostate Cancer: a Case Control Study

Jiangnan Xu,Chao Wang,Jun Ouyang,Jianglei Zhang,Zhaomin Xu
DOI: https://doi.org/10.21203/rs.3.rs-35182/v1
2020-01-01
Abstract:Background: pT0 prostate cancer is relatively rare. We wanted to share and explore the predictive clinicopathological features and prognosis of biopsy-proven pT0 prostate cancer in Chinese population.Methods: We retrospectively analyzed the clinicopathological and prognostic data of 8 patients with pT0 prostate cancer who received radical prostatectomy (RP) at our institution between 2006 and 2019. pT0 group was compared with a control group of 96 patients who underwent RP during the same period. Exclusion criteria included patients undergoing neoadjuvant hormone therapy or transurethral resection of the prostate (TURP) before the operation.Results: There were significant differences in the exposure rates of six clinicopathological features between two groups. Apart from finasteride use, the other five items were particularly frequent in the pT0 group: prostate-specific antigen (PSA) <10 ng/ml (7/8), one positive biopsy core only (7/8), biopsy Gleason score <7 (8/8), and prostate volume>40ml (7/8), length of biopsy positive for cancer≤2mm. When these five parameters were combined as predictive model, the sensitivity was 75%, the specificity was 99%. The 8 patients were followed up for an average of 67 months without biochemical recurrence or progression.Conclusions: Preoperative PSA, number of positive biopsy core, Gleason score, prostate volume, and the length of cancer can help predict pT0 stage of prostate cancer. Patients with pT0 stage had a relatively favorable prognosis.
What problem does this paper attempt to address?